Polyclinique De Limoges
- Address
- lock Available on a paid plan
Polyclinique De Limoges - Advanced Oncology Research Center
Polyclinique De Limoges is a comprehensive cancer research center conducting cutting-edge clinical trials across multiple oncologic disciplines. The center specializes in advanced cancer therapeutics, with particular expertise in targeted therapy combinations, immunotherapy, and precision medicine approaches for solid tumors.
- Breast cancer research including HER2-low, hormone receptor-positive, and triple-negative breast cancer with novel antibody-drug conjugates and CDK4/6 inhibitors
- Genitourinary oncology focusing on bladder cancer (FGFR+ alterations, BCG-unresponsive NMIBC), prostate cancer (castration-resistant and high-risk localized), and renal cell carcinoma
- Thoracic and gastrointestinal malignancies including non-small cell lung cancer, colorectal cancer with microsatellite instability, and anal squamous cell carcinoma
- Head and neck cancers and advanced melanoma with immune checkpoint inhibitors and novel combination strategies
The center demonstrates exceptional capabilities in evaluating next-generation immunotherapies, including PD-1/PD-L1 inhibitors combined with targeted agents, and innovative treatment delivery systems such as intravesical sustained-release formulations. Research programs emphasize optimizing treatment duration, de-escalation strategies in responding patients, and biomarker-driven patient selection including ctDNA monitoring and PD-L1 stratification to improve outcomes while minimizing toxicity.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 8 therapeutic areas and 15 of 76 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 76 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Polyclinique De Limoges
lock Showing 1 of 38 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy | Gilead Sciences Inc. | Phase III | Not Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 76 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 9 | Unknown | 2018-03-21 | 2025-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.